Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
J Transl Med. 2021 Sep 7;19(1):380. doi: 10.1186/s12967-021-03047-2.
The purpose of this study was to evaluate if HPV status serves as an independent predictor of early and late dysphagia outcomes when considered alongside standard patient characteristics and dose metrics for head and neck cancer patients treated with radiotherapy.
The age, sex, smoking history, cancer type (oropharyngeal vs non-oropharyngeal), HPV status, and early and late dysphagia outcomes were obtained for 99 retrospective head and neck cancer patients treated at our clinic with radiotherapy. Additionally for each patient, the mean radiation dose to the pharynx, superior/middle/inferior pharyngeal constrictor muscles, and cricopharyngeus was calculated. The predictive power of these clinical characteristics and radiation metrics was evaluated using chi-square tests for categorical variables and t-tests for continuous variables. Then multi-variate logistic models were built for each outcome using a single dose metric at a time, and either HPV status, cancer type, or both. Multi-variate models were built using both top-down and bottom-up technique to establish the most predictive independent covariates.
In the univariate analysis for early dysphagia, cancer type (p = 0.04) and four dose metrics (p ≤ 0.02) were significantly associated with outcome, while for late dysphagia, only cancer type (p = 0.04) was associated with outcome. In the multivariate analysis for early dysphagia, cancer type, smoking history, and mean dose to the five structures were consistently selected as covariates. For late dysphagia, either HPV status or cancer type was selected in each model and the mean dose to the cricopharyngeus was selected in one model.
While HPV is a known contributing factor for tumor prognosis in oropharyngeal cancers, its role in normal tissue toxicities for head and neck cancers has not previously been evaluated. Our results indicate having an oropharyngeal cancer may increase a patient's risk of high-grade early and late dysphagia while HPV status was seldom selected.
本研究旨在评估 HPV 状态是否可作为独立预测因子,用于预测接受放疗的头颈部癌症患者的早期和晚期吞咽困难结局,同时考虑患者的标准特征和剂量指标。
我们获取了 99 例在我院接受放疗的头颈部癌症患者的年龄、性别、吸烟史、癌症类型(口咽 vs 非口咽)、HPV 状态以及早期和晚期吞咽困难结局等信息。此外,还计算了每位患者的咽、上/中/下咽缩肌和环咽肌的平均放射剂量。使用卡方检验(用于分类变量)和 t 检验(用于连续变量)评估这些临床特征和放射学指标的预测能力。然后,使用单因素逻辑回归模型,逐个分析每种剂量指标,同时分析 HPV 状态、癌症类型或两者对每种结局的预测作用。使用逐步回归和完全纳入两种方法构建多变量逻辑回归模型,以确定最具预测性的独立协变量。
在早期吞咽困难的单因素分析中,癌症类型(p=0.04)和 4 项剂量指标(p≤0.02)与结局显著相关,而在晚期吞咽困难的单因素分析中,只有癌症类型(p=0.04)与结局相关。在早期吞咽困难的多因素分析中,癌症类型、吸烟史以及 5 种结构的平均剂量始终被选为协变量。在晚期吞咽困难的多因素分析中,HPV 状态或癌症类型在每个模型中被选择,环咽肌的平均剂量在 1 个模型中被选择。
HPV 是口咽癌肿瘤预后的已知影响因素,但它对头颈部癌症正常组织毒性的作用尚未得到评估。我们的结果表明,患有口咽癌可能会增加患者发生高分级早期和晚期吞咽困难的风险,而 HPV 状态很少被选择。